

Minerva Neurosciences, Inc.  
Form 8-K  
December 03, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 3, 2014**

**Minerva Neurosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36517**  
**(Commission**  
  
**File Number)**

**26-0784194**  
**(I.R.S. Employer**  
  
**Identification No.)**

**1601 Trapelo Road**  
**Suite 284**  
**Waltham, MA**  
**(Address of principal executive offices)**

**02451**  
**(Zip Code)**

**(Registrant's telephone number, including area code): (617) 600-7373**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On December 3, 2014, Minerva Neurosciences, Inc. (the Company ) announced the completion of its development and final selection of a once-daily dose formulation of MIN-101 for its schizophrenia program. The new formulation will be used in the Company s planned Phase 2b clinical trial in schizophrenia, scheduled to begin recruiting in the first half of 2015.

A copy of the Company s press release regarding the information referenced above is filed as Exhibit 99.1 to this Current Report on Form 8-K.

A copy of the Company s updated corporate presentation that includes supporting data for the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release issued by Minerva Neurosciences, Inc., dated December 3, 2014.
99.2	Presentation of Minerva Neurosciences, Inc.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MINERVA NEUROSCIENCES, INC.**

By: /s/ Mark S. Levine  
Name: Mark S. Levine  
Title: Vice President, General Counsel and  
Secretary

Date: December 3, 2014

**INDEX OF EXHIBITS**

**Exhibit**

**No.**

**Description**

99.1 Press Release issued by Minerva Neurosciences, Inc., dated December 3, 2014.

99.2 Presentation of Minerva Neurosciences, Inc.